




RealRate

PHARMACEUTICAL 2018

RELMADA THERAPEUTICS INC.
Rank 331 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2018

RELMADA THERAPEUTICS INC. Rank 331 of 349

The relative strengths and weaknesses of RELMADA THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RELMADA THERAPEUTICS INC. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 184% points. The greatest weakness of RELMADA THERAPEUTICS INC. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 798% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,135%, being 858% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	2,475
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,377
Liabilities, Non-Current	0
Other Assets	360
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	932
Property and Equipment	2.3
Research and Development	1,293
Revenues	0
Selling, General and Administrative Expense	5,925

Output Variable	Value in 1000 USD
Assets	2,837
Liabilities	1,377
Expenses	7,219
Stockholders Equity	1,460
Net Income	-6,287
Comprehensive Net Income	-6,287
Economic Capital Ratio	-1,135%

